Orforglipron (Foundayo) is now an authorised oral GLP-1 medicine in both the United States and the United Kingdom, but the authorised uses are not identical. The U.S. approval covers chronic weight management in defined adults; the UK authorisation covers defined weight-management and type 2 diabetes uses. This does not apply to unapproved look-alike products.
Still uncertain: Use outside authorised indications, long-term outcomes beyond current evidence, and equivalence of unapproved products.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
Obesity, weight management, type 2 diabetes, cardiometabolic risk
Human evidence
Large Phase III trials demonstrate clinically meaningful weight loss and glycaemic efficacy with oral orforglipron.
Regulatory status
FDA approved Foundayo (orforglipron) on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity; approval is product/indication/jurisdiction specific.
Main limitations
Use outside authorised indications, equivalence of unapproved products, or long-term outcomes beyond current evidence.
Safety
GI adverse events predominate; authorised label contains contraindications/warnings and advises against concomitant use with another GLP-1 receptor agonist.
Evidence reviewed
2026-09-18
i
Large Phase III trials demonstrate clinically meaningful weight loss and glycaemic efficacy with oral orforglipron.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Evidence rule: an outcome-specific evidence label is not a recommendation, a safety rating or an overall score for the compound.
Evidence synthesis
✓Clinically meaningful dose-dependent loss led to US approval of a bioequivalent tablet product.
✓Orforglipron is no longer merely investigational in the U.S.; FDA approved Foundayo on 1 April 2026 for chronic weight management.
✓Substantial glycaemic efficacy is demonstrated.
✓MHRA authorised Foundayo in the UK on 10 August 2026 for defined weight-management and type 2 diabetes uses; jurisdiction and indication must be stated explicitly.
Important limitations
!Trial capsule doses differ numerically from approved tablet strengths.
!Current commercial tablet strengths differ from trial dose numbers; label must govern approved dosing.
!Population was diet/exercise-treated early T2D; commercial label status should be checked separately by indication.
GI adverse events predominate; authorised label contains contraindications/warnings and advises against concomitant use with another GLP-1 receptor agonist.
Gastrointestinal adverse events are common. FDA labeling includes a boxed warning regarding thyroid C-cell tumor risk context and contraindications for MTC/MEN2, plus other GLP-1-class precautions.
Technical details
Mechanism / biologySmall-molecule partial agonism at the GLP-1 receptor, designed for once-daily oral administration without peptide injection requirements.
Route / formulation boundaryCurrent labelled Foundayo tablet strengths/dose escalation must be kept separate from numeric doses used in earlier Phase III trial publications.
Identity / data-quality noteNot a peptide. Keep investigational capsule doses and approved tablet-equivalent doses distinct.
Study / label regimen evidenceFDA-labelled dosing and Phase 3 trial dosing verified. FDA label starts at 0.8 mg tablet daily and titrates at ≥30-day intervals; ATTAIN trials used investigational capsule doses with tablet-equivalent strengths. See dosing records.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
3outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
